We are live on ! Find out more
PTLA

Portola Pharmaceuticals, Inc.
PTLA

Delisted

PTLA was delisted on the 1st of July, 2020.

159 hedge funds and large institutions have $1.24B invested in Portola Pharmaceuticals, Inc. in 2016 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 64 increasing their positions, 46 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

138% more call options, than puts

Call options by funds: $4.22M | Put options by funds: $1.78M

39% more repeat investments, than reductions

Existing positions increased: 64 | Existing positions reduced: 46

15% more capital invested

Capital invested by funds: $1.08B → $1.24B (+$158M)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

5% less funds holding

Funds holding: 167159 (-8)

21% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 28

Holders
159
Holders Change
-8
Holders Change %
-4.79%
% of All Funds
4.24%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
22
Increased
64
Reduced
46
Closed
28
Calls
$4.22M
Puts
$1.78M
Net Calls
+$2.45M
Net Calls Change
-$21.9M
Name Holding Trade Value Shares
Change
Change in
Stake
California Public Employees Retirement System
76
California Public Employees Retirement System
California
$1.03M -$34.6K -1,400 -3%
American Century Companies
77
American Century Companies
Missouri
$1.01M -$143K -5,791 -12%
BG
78
BlackRock Group
United Kingdom
$1.01M -$271K -10,993 -20%
US Bancorp
79
US Bancorp
Minnesota
$968K
Barclays
80
Barclays
United Kingdom
$889K +$743K +30,086 +397%
DA
81
DSC Advisors
Illinois
$885K
MLICM
82
Metropolitan Life Insurance Company (MetLife)
New York
$833K
Manulife (Manufacturers Life Insurance)
83
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$801K +$24.7K +1,002 +3%
Marshall Wace
84
Marshall Wace
United Kingdom
$795K -$2.31M -93,372 -73%
UBS Group
85
UBS Group
Switzerland
$786K +$735K +29,771 +847%
D.E. Shaw & Co
86
D.E. Shaw & Co
New York
$768K +$333K +13,487 +71%
Citadel Advisors
87
Citadel Advisors
Florida
$762K -$2.38M -96,555 -75%
PA
88
Profund Advisors
Maryland
$752K -$29.3K -1,185 -4%
TRSOTSOK
89
Teachers Retirement System of the State of Kentucky
Kentucky
$741K +$87.2K +3,530 +13%
DekaBank Deutsche Girozentrale
90
DekaBank Deutsche Girozentrale
Germany
$679K +$51.8K +2,100 +8%
CAM
91
ClariVest Asset Management
California
$674K +$93.8K +3,800 +15%
AIG
92
American International Group
New York
$669K -$79.5K -3,219 -10%
TC
93
TFS Capital
Pennsylvania
$639K +$70K +2,834 +12%
Tudor Investment Corp
94
Tudor Investment Corp
Connecticut
$584K -$140K -5,681 -19%
State Board of Administration of Florida Retirement System
95
State Board of Administration of Florida Retirement System
Florida
$532K +$31.3K +1,268 +6%
RIL
96
Rothschild Investment LLC
Illinois
$523K +$77.3K +3,130 +16%
Creative Planning
97
Creative Planning
Kansas
$497K +$117K +4,755 +29%
FRM
98
Fox Run Management
Connecticut
$496K -$143K -5,800 -22%
VFA
99
Virtus Fund Advisers
Connecticut
$486K +$157K +6,339 +45%
TD Asset Management
100
TD Asset Management
Ontario, Canada
$425K -$14.8K -600 -3%

PTLA Hedge Fund Activity: Q2 2016 in Review

159 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Portola Pharmaceuticals, Inc. (PTLA) for Q2 2016, worth a combined $1.24B — up 15% from $1.08B a quarter earlier.

Sellers outnumbered buyers: 28 funds closed out of PTLA and 22 opened new positions — a net loss of 6 holders — while 46 trimmed existing stakes and 64 added.

The largest buyer was Pictet Asset Management (UK), adding an estimated $15M. The largest seller was Franklin Resources, cutting an estimated $18.3M.

  • 159 institutional investors held Portola Pharmaceuticals, Inc. (PTLA) as of Q2 2016, down from 167 in Q1 2016.
  • Funds reported $1.24B of Portola Pharmaceuticals, Inc. stock for Q2 2016, up 15% quarter-over-quarter.
  • 22 funds opened new Portola Pharmaceuticals, Inc. positions in Q2 2016 and 28 closed out, a net change of -6 holders.
  • The largest Portola Pharmaceuticals, Inc. buyer in Q2 2016 was Pictet Asset Management (UK), an estimated $15M added.
  • The largest Portola Pharmaceuticals, Inc. seller in Q2 2016 was Franklin Resources, an estimated $18.3M sold.

Based on aggregated 13F filings for Q2 2016.